Exact Sciences - Stock Price History | EXAS

Historical daily share price chart and data for Exact Sciences since 2021 adjusted for splits. The latest closing stock price for Exact Sciences as of October 22, 2021 is 93.98.
  • The all-time high Exact Sciences stock closing price was 155.01 on February 12, 2021.
  • The Exact Sciences 52-week high stock price is 159.54, which is 69.8% above the current share price.
  • The Exact Sciences 52-week low stock price is 89.65, which is 4.6% below the current share price.
  • The average Exact Sciences stock price for the last 52 weeks is 119.90.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Exact Sciences Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 92.2277 95.5800 142.1200 37.9000 132.4900 43.26%
2019 97.0584 64.1400 122.4900 61.9800 92.4800 46.56%
2018 59.1706 51.7900 82.6600 37.8400 63.1000 20.10%
2017 36.1470 13.4100 60.5100 13.4100 52.5400 293.26%
2016 11.9728 9.0000 21.4900 4.9400 13.3600 44.75%
2015 20.6162 26.7900 31.1600 7.1300 9.2300 -66.36%
2014 17.5492 11.8200 29.6500 11.1700 27.4400 133.53%
2013 11.5220 11.0500 14.4700 8.1400 11.7500 10.95%
2012 10.0498 8.0700 11.8900 7.9300 10.5900 30.42%
2011 7.2547 6.1800 9.2000 4.9700 8.1200 35.79%
2010 4.9898 3.4000 8.9200 3.3100 5.9800 76.40%
2009 2.0877 0.5800 3.3900 0.5800 3.3900 494.74%
2008 1.5940 3.3801 3.4700 0.3500 0.5700 -82.30%
2007 3.1721 2.7200 6.0200 2.3299 3.2200 13.78%
2006 2.3746 2.3200 4.2600 1.6300 2.8300 28.05%
2005 2.6917 3.7400 4.6500 1.3400 2.2100 -42.30%
2004 5.6878 10.1500 10.2500 2.4600 3.8300 -62.15%
2003 11.4645 11.5400 17.5500 6.5000 10.1200 -6.56%
2002 11.8529 10.2500 16.5800 7.9000 10.8300 5.56%
2001 9.3984 15.0000 15.1700 5.3000 10.2600 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $16.160B $1.491B
EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76